Lakefront Biotherapeutics (LKFT) Invested Capital (2020)

Lakefront Biotherapeutics (LKFT) has reported Invested Capital for 11 consecutive years, with $46.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Invested Capital fell 55.38% year-over-year to $46.0 million; the TTM figure through Mar 2026 stood at $46.0 million (down 55.38% YoY), while the FY2025 annual figure was $46.0 million, down 55.38% from the prior year.
• Invested Capital eased to $46.0 million in Q4 2025 per LKFT's latest filing, from $103.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $127.6 million in Q4 2021 and bottomed at $404635.2 in Q2 2021.
• Historically, Invested Capital has averaged $75.3 million across 5 years, with a median of $103.2 million in 2024.
• Annual changes were most pronounced in 2021 — Invested Capital tumbled 98.65% — and 2023, when it increased 4.92%.
• Lakefront Biotherapeutics' Invested Capital stood at $127.6 million in 2021, then decreased by 4.78% to $121.5 million in 2022, then rose by 4.92% to $127.5 million in 2023, then retreated by 19.12% to $103.2 million in 2024, then plunged by 55.38% to $46.0 million in 2025.
• Business Quant data shows LKFT's Invested Capital at $46.0 million in Q4 2025, $103.2 million in Q4 2024, and $127.5 million in Q4 2023.